Hypertriglyceridemia

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
  A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay…
  biospace · 7d ago
• Lisata deal propels Marea’s drug pipeline to Wall Street
  Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.
  biopharma_dive · 13d ago
• After one failed acquisition attempt, Lisata finds lifeline in Marea merger
  After a failed merger that led to massive layoffs and a lawsuit, solid tumor biotech Lisata Therapeutics has found a new future through a merger with cardio specialist Marea Therapeutics.
  fiercebiotech · 13d ago
• Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
  Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
  fiercebiotech · 16d ago
• FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
  Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neuro…
  biospace · 26d ago
• ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
  At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
  biopharma_dive · 1mo ago
• Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
  Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
  biospace · 1mo ago
• Scribe’s early-stage IPO standout defies biotech’s derisking trend
  Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
  biospace · 1mo ago
• FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
  The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and old…
  fda_press · 1mo ago
• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
  biopharma_dive · 1mo ago